Results for tag: "Portrazza"

Portrazza is a type of lung cancer drug that belongs to a class of drugs known as epidermal growth factor receptor (EGFR) inhibitors. It is used to treat non-small cell lung cancer (NSCLC) in patients whose tumors have a specific genetic mutation known as EGFR exon 19 deletion or exon 21 L858R substitution mutations. Portrazza works by blocking the activity of the EGFR protein, which helps to slow the growth and spread of cancer cells. Portrazza is approved by the US Food and Drug Administration (FDA) for the treatment of metastatic NSCLC in patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations. It is also approved for use in combination with other chemotherapy drugs. Portrazza is marketed by Eli Lilly and Company, and is available in the United States, Europe, and other countries. Other companies that market similar drugs include AstraZeneca, Boehringer Ingelheim, and Roche. Show Less Read more